Glaxo, Vir Halt Enrollment in Study of Covid Antibody Treatment
(Bloomberg) -- GlaxoSmithKline Plc and Vir Biotechnology Inc. halted enrollment in a late-stage study of a Covid-19 antibody therapy on the recommendation of an independent monitoring board.
The study is looking at the effects of VIR-7831 in hospitalized patients, and the action was taken after “sensitivity analyses of the available data raised concerns about the magnitude of potential benefit,” according to a statement from the companies. The independent Data and Safety Monitoring Board “recommended that the VIR-7831 arm of the trial be closed to enrollment while the data mature.”
Doctors are looking for therapies to counter Covid-19, and London-based Glaxo and San Francisco-based Vir are working with the U.S. National Institutes of Health on studies of the antibody therapy. Other antibodies from Eli Lilly & Co. and Regeneron Pharmaceuticals Inc. have received authorizations for emergency use from U.S. regulators.
Vir fell as much as 30% as of 9:36 a.m. in New York. Glaxo fell 0.6% in London.
A study of the drug in non-hospitalized Covid-19 patients is expected to read out by the end of this quarter. The companies will continue discussions with the NIH about how to assess the treatment's impact in hospitalized patients, according to the statement.
There were no reported safety signals from the treatment, according to the statement.
Glaxo invested $250 million in Vir last year.
©2021 Bloomberg L.P.
-
Navigating Energy Crossroads: S Jaishankar's Call For Diversified Supply Chains At G20 Ministerial Meeting
As geopolitical fault lines continue to test maritime trade routes and commodity flows, Jaishankar's message remains pertinent: true economic resilience requires open markets, protected transit lines, and a genuine commitment to multilateral cooperation rather than coercion.
-
Indians Are Travelling, But Not Every Journey Is A Holiday | The Week In Whys
Pilgrims, patients and working women are the real travellers, and the system hasn't quite caught up with them.
-
Getting To Work Costs Women More | The Reason Why
It is not just about women paying more than men. It is about women paying much more in cities than in villages.
-
AI Bias In Investing Cannot Be Eliminated, But It Can Be Governed
Framing is a particularly important example as identical financial information presented in terms of gains rather than losses can lead an LLM to reach a different assessment.
-
Joining The Dots | Dark Skies, Steady Diya: Why Hope Holds This Diwali
With war, a weak rupee and foreign outflows weighing on sentiment, policymakers at the NDTV World Summit and market veterans at NDTV Profit Ignite: Diwali Edition offered the same advice: stay invested and filter out the noise.
-
The Curious Case of Equitas Small Finance Bank And A CEO Who Quit For Stock
PN Vasudevan believes persistent investor concerns over a perceived conflict of interest had become a governance overhang on Equitas Small Finance Bank's stock, even as the lender improved profitability and asset quality.
-
Talking Points This Week: AI Cash Burn, A Tiger Comeback And An India That Still Finds Its Own Path
India is not immune to higher oil or tighter global liquidity, yet its earnings base is broader, its domestic policy levers are still available.
-
Foreign Investors Own Half Of HDFC Bank and ICICI Bank. An LTCG Cut Could Matter Most Here
Foreign portfolio investors have US$115 billion parked in HDFC Bank, ICICI Bank. If the government cuts long-term capital gains tax, Jefferies says returning foreign money could land here first.
-
'Never Seen This Level Of Negativity': Sandeep Tandon Says The Next Rally May Be Closer Than You Think
Veteran investor Sandeep Tandon says foreign selling is easing, large-caps are due a comeback and mid-caps are crowded, while he turns positive on gold, power and pharma this Diwali.
-
Indians Stay With Family, Not In Hotels | The Reason Why
India still lacks enough clean, reliable and affordable hotels for budget-conscious travellers.
